go back

Lisocabtagene Maraleucel (Breyanzi) CAR-T Therapy

Arkansas rates for HCPCS Q2054

Lisocabtagene maraleucel, up to 110 million autologous anti-CD19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $676,083 · 10th–90th $676,083$707,9460%50%90th$676,083Professionalmedian $562,341 · 10th–90th $562,341$676,0830%50%90th$562,341$500.0K$1.0M$2.0M$5.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Facility
Modifier
Global
Typical Low
$676,082.98
Median
$676,082.98
Typical High
$707,945.78
Aetna
Setting
Professional
Modifier
Global
Typical Low
$562,341.33
Median
$562,341.33
Typical High
$676,082.98
Cigna
Setting
Professional
Modifier
Global
Typical Low
$562,341.33
Median
$562,341.33
Typical High
$676,082.98
United
Setting
Facility
Modifier
Global
Typical Low
$562,341.33
Median
$562,341.33
Typical High
$562,341.33
United
Setting
Professional
Modifier
Global
Typical Low
$346,736.85
Median
$512,861.38
Typical High
$870,963.59